Want another chance to ask Marianne and Chris about modeling IBD pathogenesis on the Colon Intestine-Chip? Join us for an encore Q&A session on Moxi, the social network for Organ-on-a-Chip technology, on Friday, June 2nd, from 11am–12pm EDT.
Inflammatory bowel disease (IBD) represents an enormous area of unmet medical need. Despite ~10 million people suffering from IBD globally, ~50% of patients fail to respond to on-market therapy, and 90% fail to experience long-term remission.
The limited efficacy of IBD therapeutics is due in part to the limited human relevance of conventional preclinical models, which restrict researchers to studying just one aspect of IBD at a time. These models may allow researchers to evaluate drug efficacy in isolation, but fail to accurately predict drug effects within the complex intestinal microenvironment, leading to high clinical trial failure rates.
It’s time for a human-centric approach to IBD drug discovery and development.
In this webinar, Marianne Kanellias discussed how researchers can use Emulate Organ-on-a-Chip technology to create a more representative and complex model of IBD pathogenesis. With the Emulate human Colon Intestine-Chip, researchers can recapitulate the inflammatory response of IBD—from immune cell vascular attachment, to migration, to downstream effector function and barrier damage—and evaluate the efficacy of anti-inflammatory therapeutics in a more human-relevant model of IBD.
This presentation included new data generated since the 2022 launch of Emulate’s immune cell recruitment application, including therapeutic assessment of anti-TNFα inhibitors, immuno-phenotyping analysis, and the assessment of additional clinically relevant biomarkers.
Key highlights from this IBD webinar:
- Common challenges in modeling inflammatory disease
- Recreating gut- and inflammation-specific immune cell recruitment with the Colon Intestine-Chip
- Evaluating clinically relevant IBD therapeutics across a range of mechanisms of action
- A panel discussion and live Q&A with Marianne Kanellias and Chris Carman, PhD who led the development of the immune cell recruitment application for the Colon Intestine-Chip